Hematologic Malignancy
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified by Gene Expression Profile
CI-CAN-00008841Explore in graph →
Hematologic12 active trials4 evidence items
- NCIt
- C45219
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00008841Explore in graph →
Clinical trials
20 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (4)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05294731 | Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader | recruiting | Phase 1 / Phase 2 | 146 | BeiGeneINDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05755087 | Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma | recruiting | Phase 1 | 18 | Lapo AlinariOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| Study of SGR-1505 in Mature B-Cell Neoplasms |
| recruiting |
| Phase 1 |
| 98 |
| Schrödinger, Inc.INDUSTRY |
| 8 |
| Feb 13, 2026 |
| clinicaltrials |
Data updated 22 days agoSource updated Aug 21, 2026source: clinicaltrials